To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

April 17, 2019

Today's Rundown

Featured Story

The king is dead, long live the king: Sharpless vows to continue Gottlieb era at FDA

Scott Gottlieb’s relatively short two-year tenure as the FDA’s head has ended, and we have a new man at the helm: Ned Sharpless. However, he used his first official talk to ensure we all know he’s not looking to tear up Gottlieb’s legacy.

Top Stories

GSK warns of possible layoffs as Barron's revised R&D strategy takes effect

GlaxoSmithKline is set to lay off a small number of R&D employees at its Stevenage, U.K., site as part of a wider rethink of its drug development operation. The layoffs come as GSK revises its R&D strategy under the scientific leadership of Hal Barron.

Kiadis to buy CytoSen, adding June to advisory board

Kiadis is set to buy CytoSen Therapeutics to expand into anti-cancer natural killer cell therapies. The all-stock transaction will give Kiadis control of a preclinical NK cell therapy and see it add CAR-T pioneer Carl June to its scientific advisory board.

[Sponsored] Mitotech: a Dry Eye treatment aimed at mitochondria

Mitotech – a biotech specializing in targeting mitochondria – is moving into late stage of clinical development in Dry Eye Disease.

Nocion launches with $27M and 'charged drugs' to selectively target pain

Nocion is working on positively charged molecules that silence nociceptors—the neurons that send pain or itch signals—without affecting other neurons. The hope is to come up with drugs that treat pain without causing numbness, paralysis and other side effects.

FDA orders Boston Scientific, Coloplast to halt transvaginal mesh sales

Boston Scientific and Coloplast—the two remaining U.S. manufacturers of transvaginal surgical mesh—have been ordered by the FDA to halt the sale and distribution of those products across the country, effective immediately.

Resources

[Whitepaper] Personalized Test for Treatment Prediction in Depression

Total Brain Announces Personalized Test for Treatment Prediction in Depression with 80% Accuracy.

[Whitepaper] Observed Impact of Medication Price Transparency on Patients and Practices

Prescription price transparency technology is here – but is it making a difference? Find out HERE.

[Whitepaper] Redefining Your Value to Win Empowered Patients: Six Steps to Success

Every life sciences firm talks about patient-centricity, but are you doing what it takes to deliver?

[Whitepaper] Key Life Sciences Trends, 2019 and Beyond

The year’s biggest compliance and technology trends in life sciences. Learn about the latest trends impacting the biotech, medical device and pharmaceutical industries.

[Whitepaper] The New World of Allosteric Modulation: Another Shot on Goal

Learn how to utilize allosteric modulation to maximize its full potential in drug discovery programs. Download this white paper to learn more.

[Whitepaper] Advanced HDX-MS and Native-MS for Improved Biologic Candidate Selection and Development

Discussion of the potential for improving biologic drug development success through earlier, strategic application of advanced mass spectrometry, because currently, with most biologic drugs, including gene therapies, failures are realized in late-stage development, after substantial investment has been made in a candidate.

[Whitepaper] Workbench for Biomarker and Translational Research

Clinical trials and biomarker data from patients when unified, harmonized, and made searchable; is a rich, reliable and controlled resource for research. This paper sets out the requirements for a Translational and Biomarker Research Workbench for scientists using the experiences from use of Xbiom™ at BioPharma.

[Whitepaper] Meet Our Uncle: 12 Protein Stability Applications on One Platform

Download this whitepaper to learn more!

[Whitepaper] Flow Chemistry For Modern API Development & Manufacturing

Is Flow Chemistry right for your API Development?

[Whitepaper] Systolic Heart Failure: Real-World Study Using Electronic Health Records

Real-World case study by Veradigm suggests that new medications specifically approved for the treatment of systolic heart failure may be underutilized despite being important advances in patient care.

[Article] Are you ready for 2008 Microsoft SQL and Windows Servers end of life?

Software end of life puts you at risk for data breaches, business disruption and liability. Support for Microsoft SQL Server 2008/2008 R2 and Windows Server 2008/2008 R2 ends on July 9, 2019 and January 14, 2020, respectively. Learn how you can turn these risks into a strategic business advantage.

[Whitepaper] Better Market Intelligence With Smart Search

From new regulations to drug pricing and the latest M&A deals, learn how AI is making it easier for competitive intelligence to uncover the insights they need to stay ahead of the curve.

[Whitepaper] Accelerating Clinical Trials through Access to Real-World Patient Data

Whitepaper on leveraging normalized real-world patient data to streamline clinical trials, reduce delays and lower costs.

[Case Study] TriCore Reference Laboratories Transforms to Clinical Lab 2.0 Model

Analytics using patients’ real-time longitudinal laboratory results, and claims data, yielded higher value information and new revenue streams for TriCore reference laboratories.

[eBook] 2018 Weekly Compendium

The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry.

Events